Please login to the form below

Not currently logged in

NICE backs two cancer drugs

Boehringer’s Giotrif and Janssen’s Velcade given final go-ahead for NHS use
National Institute for Health and Care Excellence NICE logo

The National Institute for Health and Care Excellence (NICE) has given definitive backing to two cancer drugs for routine use on the NHS in England and Wales.

Cost-effectiveness body NICE issued final guidance recommending Boehringer Ingelheim's Giotrif (afatinib) for use in the treatment of lung cancer, while Janssen's Velcade (bortezomib) was given the green light to treat blood cancer multiple myeloma.

With its recommendation, Giotrif becomes the third drug recommended by NICe that is a personalised treatment for people with non-small-cell lung cancer (NSCLC).

It follows positive guidance for personalised lung cancer medicines Roche's Tarceva (erlotinib) and AstraZeneca's Iressa (gefitinib), both of which are also targeted at patients who have the EGFR-TK genetic mutation.

The specific recommend for Giotrif covers patients who have non-small-cell lung cancer which is locally advanced or has spread to other parts of the body.

The NICE recommendation is another positive step forward for Boehringer's relatively new oncology ambitions, which bore its first fruit with the approval of Giotrif last year.

Elsewhere, NICE backed Janssen's Velcade as a first treatment for people with multiple myeloma before bone marrow transplant.

“The evidence presented to our independent committee showed that having bortezomib at this stage will help more patients go on to a bone marrow transplant, and consequently prevent the disease from progressing for longer,” said Professor Carole Longson, director of the NICE centre for health technology evaluation.

The decision comes after a troubled review period for Velcade, which was initially turned down in this indication in 2013.

Article by
Thomas Meek

23rd April 2014

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Double Helix

Double Helix is an independent healthcare consultancy with headquarters in London and offices in the US and Singapore. Established in...

Latest intelligence

What is a patient-centric brand anyway?
It’s hard to believe that in our industry, there have been ongoing rumblings about patient-centricity for years now. Sure, there are some great companies who have worked hard to bring...
‘Less Is More: Making Patient-Centered Digital Communication a Reality’
Letizia Affinito writes on the Gower Publishing blog....
The Seven Cs Of Cross-Functional Brand Planning
As more and more organisations have moved to cross-functional and cross-regional involvement in the development of their strategic and operational brand plans, the result has been greater engagement and alignment,...